In race to lead the TIGIT pack in I/O, Roche delivers positive PhII data — but big questions linger
Expectations over Roche’s anti-TIGIT drug tiragolumab have been growing steadily in the buildup to ASCO. As the lead drug in the field pursuing second-generation status in immuno-oncology, it marks a potential major advance over the first generation of I/O drugs in the market.
And on Wednesday’s data drop, the pharma giant’s big sub Genentech delivered the data, which was quickly — and not always favorably — compared closely with Merck’s dominant drug Keytruda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.